- Home
- CTSH vs TAK Comparison
CTSH vs TAK Comparison
Compare CTSH & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTSH | TAK |
|---|---|---|
| Founded | 1994 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 56.5B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTSH | TAK |
|---|---|---|
| Price | $60.50 | $17.75 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $89.27 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 2.4M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | 2.16% | ★ 2.97% |
| EPS Growth | ★ 1.11 | N/A |
| EPS | ★ 4.56 | N/A |
| Revenue | ★ $21,108,000,000.00 | N/A |
| Revenue This Year | $8.19 | $0.04 |
| Revenue Next Year | $5.09 | $0.92 |
| P/E Ratio | ★ $13.42 | $41.25 |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $60.04 | $12.99 |
| 52 Week High | $87.03 | $18.82 |
Technical Indicators
Market Signals| Indicator | CTSH | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 46.62 |
| Support Level | $60.04 | $17.51 |
| Resistance Level | $67.99 | $18.82 |
| Average True Range (ATR) | 1.82 | 0.25 |
| MACD | 0.26 | -0.15 |
| Stochastic Oscillator | 5.54 | 20.04 |
Price Performance
Historical ComparisonAbout CTSH Cognizant Technology Solutions Corporation
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.